Recombinant Human FGFR4 protein (C-rFc)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg3510
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <1.0 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human FGFR4 protein Leu22-Asp369 (Accession# P22455-1) with a rabbit IgG Fc tag at the C-terminus. |
| GeneID | 2264 |
| Accession | P22455-1 |
| PredictedSize | 64.8 kDa |
| SDS-PAGE | |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Fibroblast growth factor receptor 4 (FGFR4) is a member of a highly conserved tyrosine kinase family, along with FGFR1-3. This family consists of an intracellular tyrosine kinase domain, a single transmembrane domain, and extracellular ligand-binding domains. FGFR4 is the predominant FGFR isoform present in human hepatocytes. FGFR4 has been proposed to play a role in the observed induction of hepatocyte proliferation and carcinogenesis by FGF19; however, contradicting evidence proposing a protective role for FGFR4 in suppressing hepatoma progression has also been proposed. While the role of FGFR4 in cancer remains to be fully elucidated, several findings suggest that this receptor may be an important player in Hepatocellular carcinoma (HCC) development and/or progression.
References:
1. Levine, Kevin M et al. Pharmacology & therapeutics vol. 214 (2020): 107590. 2. Wu, Xinle et al. The Journal of biological chemistry vol. 285,8 (2010): 5165-70. 3. Kan, M et al. The Journal of biological chemistry vol. 274,22 (1999): 15947-52.